Follow us on Twitter
twitter icon@FreshPatents


Allergic Rhinitis patents

      

This page is updated frequently with new Allergic Rhinitis-related patent applications.




 Novel compounds patent thumbnailNovel compounds
Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

 New pyrazolyl-substituted heteroaryls and their use as medicaments patent thumbnailNew pyrazolyl-substituted heteroaryls and their use as medicaments
And the use of these aforementioned compounds for the treatment of diseases such as asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .

 Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon patent thumbnailPyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
Wherein r1 is hydrogen, methyl or —(ch2)2or3, r2 is methyl or —(ch2)2or4, or r1 and r2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; r3 and r4 are each independently hydrogen or methyl; and n is an integer having a value of 5 or 6, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment or prevention of various disorders, for example the treatment or prevention of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

 Trk-inhibiting compound patent thumbnailTrk-inhibiting compound
The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an n-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease..
Ono Pharmaceutical Co., Ltd.


 Oral controlled release pharmaceutical compositions of bepotastine patent thumbnailOral controlled release pharmaceutical compositions of bepotastine
The present invention relates to oral controlled release pharmaceutical compositions comprising bepotastine. The oral controlled release pharmaceutical composition comprises bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent.
Lupin Limited


 Heteroaryl syk inhibitors patent thumbnailHeteroaryl syk inhibitors
The invention relates to new substituted heteroaryls of formula 1 wherein a is selected from the group consisting of n and ch d is selected from the group consisting of ch, n, nh, e is c, t is selected from the group consisting of c and n, g is selected from the group consisting of c and n, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein r1, m and r3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .
Boehringer Ingelheim International Gmbh


 Therapeutic agent for rhinitis patent thumbnailTherapeutic agent for rhinitis
Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising c-type natriuretic peptide (cnp) or b-type natriuretic peptide (bnp) as the active ingredient.. .

 Ionic aqueous compositions patent thumbnailIonic aqueous compositions
Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e.g., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e.g., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such as branched, sulfated polysaccharides having an average molecular weight greater than 4 kda and comprising l-fucose and sulfate ester groups or extracts from brown algae.
Gerolymatos International S.a.


 Use of egg yolk oil and the benzopyrene-eliminated egg yolk oil in the treatment of allergic rhinitis patent thumbnailUse of egg yolk oil and the benzopyrene-eliminated egg yolk oil in the treatment of allergic rhinitis
The application of egg yolk oil, as well as benzopyrene-eliminated egg yolk oil, is prepared for medicaments for the treatment of allergic rhinitis. By topical application of egg yolk oil in the nasal cavity, symptoms of allergic rhinitis could be improved significantly.
Harbin Medical University


 Materials for treating and preventing mucosa related disease patent thumbnailMaterials for treating and preventing mucosa related disease
Provided is a hyaluronic acid (ha) composition for use in treating or preventing mucosa related disorders or diseases including a mixture of has having different average molecular weights and different rheological, isolation, tissue scaffold and degradation properties. The resulting formulation demonstrates an optimal balance between adhesion, tissue scaffold and treating time on the treatment and prevention of mucosa related disorders or diseases including conjunctivitis, otitis, allergic rhinitis, gingivitis, oral ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), irritable bowel syndrome (ibs), urethritis, cystitis and vaginitis..
Aihol Corporation


Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

Pharmaceutical composition including dead cells of lactobacillus acidophilus lb to treat or prevent allergic disease

Disclosed is a pharmaceutical composition including dead cells of lactobacillus acidophilus lb strain as an active ingredient for treating or preventing an allergic disease, and may be used to treat and prevent ige-mediated allergic diseases and non-ige-mediated allergic diseases such as atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, and pollinosis by reducing the total content of ige in the blood.. .

Human antibody molecules for il-13

Specific binding members, in particular human anti-il-13 antibody molecules and especially those which neutralize il-13 activity. Methods for using anti-il-13 antibody molecules in diagnosis or treatment of il-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and hodgkin's lymphoma..
Medimmune Limited

Trk-inhibiting compound

The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an n-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease..
Ono Pharmaceutical Co., Ltd.

Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

The present invention relates to novel biologically active glutarimide derivatives of general formula (i) or a pharmaceutically acceptable salt thereof, their use as a therapeutic agent for the treatment of eosinophilic diseases, preferably of allergic nature, in particular bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, eosinophilic colitis, eosinophilic syndrome, allergic conjunctivitis, atopic dermatitis, churg-strauss syndrome, anaphylactic shock, quincke's edema, eosinophilic vasculitis, eosinophylic esophagitis, eosinophilic gastroenteritis, or fibroses. The invention also relates to pharmaceutical compositions comprising glutarimide derivatives of general formula (i):.
Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises"

Azelastine formulations for intranasal nebulization and irrigation

A method of treating allergic rhinitis includes nebulizing a formulation including azelastine in an aqueous solution. Nebulizing the formulation produces nebulized particles for intranasal delivery to the patient.
Cmpd Licensing, Llc

Heteroaryl syk inhibitors

The invention relates to new substituted heteroaryls of formula (1), wherein a is selected from the group consisting of n and ch, d is ch, e is selected from the group consisting of c and n, t is c, g is selected from the group consisting of c and n, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein r1, m and r3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. .
Boehringer Ingelheim International Gmbh

Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists

The present invention relates to compounds of formula (i), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where r1 and r2 are, independently, hydrogen, halogen, c1_3 alkyl or c1-3alkoxy; r3 is phenyl optionally substituted by r4 and r5 which are, independently hydrogen, halogen, c1-3 alkyl, c1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, n,n-dic1-3alkyl-amide, carboc1-3 alkoxy or c1-3alkylsulphone groups; r3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.. .
Polfarmex S.a.

Histamine-3 receptor antagonists

The invention is directed to a compound of formula i, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula i; and a method of treatment of a disorder or condition selected from the list consisting of acute myocardial infarction; memory processes disorders; dementia; cognition disorders such as alzheimer's disease; attention deficit disorder (add); attention-deficit hyperactivity disorder (adhd); cancers such as cutaneous carcinoma, medullary thyroid carcinoma and melanoma; meniere's disease; gastrointestinal disorders; inflammation; migraine; motion sickness; obesity; pain; septic shock; respiratory disorders (including allergic rhinitis, nasal congestion and allergic congestion) in a mammal, including a human, that may be effected by administering to said mammal a pharmacologically effective amount of a compound of formula i, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.. .
Medisynergics, Llc

6-amino-purin-8-one compounds

Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Composition for use in treating and preventing inflammation related disorder

The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (ha) or ha mixture, whereas the ha or the ha mixture as a delivery vehicle can be a formulation including at least two has having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (gerd), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (ibd), crohn's disease, irritable bowel syndrome (ibs), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis..
Aihol Corporation

Device and treating allergic rhinitis

A device for delivering light to a nasal cavity is provided. The device has a base at a proximal end of the device.
Lumimed, Llc

Stat6 inhibitors

The present disclosure provides compounds that are useful for inhibiting the stat6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds.
Board Of Regents, The University Of Texas System

Capsule formulation comprising montelukast and levocetirizine

Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects..
Hanmi Pharm. Co., Ltd.

Method and chamber for exposure to non-allergic rhinitis trigger environments

The present invention is a method and chamber for exposure of human subjects to non-allergic rhinitis (“nar”) trigger environments. The method occurs in a nar chamber and involves tests that expose subjects to environmental triggers known to induce nar symptoms.
Inflamax Research, Inc.

P2x7 modulators

The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

Pyrazolopyrimidine compounds

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

P2x7 modulators

The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

Furo [3, 2-b] pyrr0l-3-0nes as cathespin s inhibitors

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

Methods of purifying anti-interleukin-13 antibodies

The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and hodgkin's lymphoma, particularly asthma.. .
Medimmune Limited

Trk-inhibiting compound

The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an n-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease..
Ono Pharmaceutical Co., Ltd.

Novel use of rice, rice bran or rice hull extract as an histamine receptor antagonist

Disclosed is a use of rice, rice bran or rice hull extract as a histamine receptor antagonist. The rice, rice bran or rice hull extract may be used as a natural antihistamine to prevent or treat allergic rhinitis, inflammatory bowel disease, asthma, bronchitis, nausea, gastric and duodenal ulcer, gastroesophageal reflux disease, sleep disorder, anxiety and depression.
Korea Food Research Institute

Novel compounds

Wherein r1 is n-c3-6alkyl; r2 is hydrogen or methyl; r3 is hydrogen or c1-6alkyl, and m is an integer having a value of 1 to 4; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Novel compounds

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Treatment of allergic rhinitis using a combination of mometasone and olopatadine

The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.. .
Glenmark Pharmaceuticals Limited

Novel compounds

Wherein r1 is n-c3-6alkyl; r2 is hydrogen or methyl; r3 is hydrogen or c1-6alkyl, and m is an integer having a value of 0 to 3; are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Balloon system for treating sinusitis or allergic rhinitis

A balloon system for treating sinusitis or allergic rhinitis includes a central inner tube, a balloon to be filled and a balloon catheter outer tube, all of which axially extend. The central inner tube includes a distal end part and a proximal end part detachably connected with each other by a connector in an axial direction.
Puyi (shanghai) Biotechnology Co., Ltd

Methods of using anti-il13 human antibodies

The present invention relates to human anti-il-13 binding molecules, particularly antibodies, and to methods for using anti-il-13 antibody molecules in diagnosis or treatment of il-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and hodgkin's lymphoma.. .
Novartis Ag

Compounds having crth2 antagonist activity

And their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.. .

2-(-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors

The present invention relates to compounds of formula (ia), (ib) or (ic): to pharmaceutically acceptable salts therefore fore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma, copd, allergic rhinitis, chronic sinusitis, atopic dermatitis, psoriasis, rosacea, alopecia, allergic conjunctivitis and dry eye disease. .
Ziarco Pharma Ltd.

Pyrazolopyrimidine compounds

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Use of arginase inhibitors in the treatment of asthma and allergic rhinitis

The present invention relates to the use of an arginase inhibitor for the preparation of a medicament for the prophylactic maintenance therapy of an asthmatic or allergic patient by preventing obstruction of upper and lower airways, in particular allergen-induced bronchial obstruction and/or airway hyperresponsiveness. The patients are either asthmatic or have allergic rhinitis.
Rijksuniversiteit Groningen

Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .

Use of composition in preparing health care products or medicines for preventing and treating allergic diseases

The present invention relates to use of a composition in the manufacture of health care products or medicaments for prevention and treatment of allergic diseases. The composition is made from raw materials comprising 5 to 200 parts by weight of ganoderma, 5 to 150 parts by weight of radix panacis quinquefolii or radix et rhizoma ginseng, 1 to 90 parts by weight of fermented cordyceps sinensis powder and/or 1 to 120 parts by weight of cordyceps, or is a composition made from water and/or alcohol extracts of the above raw materials as active components.
Jiangzhong Pharmaceutical Co., Ltd.

Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis

The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions..
Nuvo Research Ag

Compositions and methods for the treatment of respiratory disorders

The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Trk-inhibiting compound

(wherein all symbols represent the same meanings as described in the specification), a salt thereof, an n-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease.. .

Implanted system for treating sinusitis or allergic rhinitis

An implanted system for treating sinusitis or allergic rhinitis is provided, wherein the implanted system has a circumferentially extending wall formed of a biodegradable polymer, and the wall includes a plurality of interspaces, with biodegradable fiber bundles containing drugs interspersed in the interspaces. The implanted system formed of the biodegradable polymer can provide a sufficient normal force perpendicular to the external surface during a compression, and prevent the supported channel from being closed after the release in a location for the implantation (a location of pathological changes or ostium of the sinus).
Puyi (shanghai) Biotechnology Co., Ltd.

Treatment of allergic rhinitis using a combination of mometasone and olopatadine

The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.. .
Glenmark Pharmaceuticals Limited

Compositions and methods for the treatment of muscle pain

The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i; and methods for treating or preventing muscle pain, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.



Allergic Rhinitis topics:
  • Allergic Rhinitis
  • Dermatitis
  • Multiple Sclerosis
  • Bowel Disease
  • Inflammatory Bowel Disease
  • Inflammation
  • Atherosclerosis
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Atopic Dermatitis
  • Bronchopulmonary
  • Sudden Infant Death
  • Staurosporin
  • Sudden Infant Death Syndrome
  • Effective Dose


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Allergic Rhinitis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergic Rhinitis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4389

    file did exist - 2647

    1 - 1 - 50